Disc Medicine, Inc. (NASDAQ:IRON) announced it will present data from multiple programs in its hematology portfolio at the European Hematology Association (EHA) 2025 Congress in Milan, Italy, scheduled for June 12-15, 2025. The clinical-stage biopharmaceutical company focuses on developing novel treatments for patients with serious hematologic diseases.
Portfolio Progress Across Multiple Programs
"As we progress toward major company milestones in the second half of 2025, this year's EHA presentations showcase steady progress across our pipeline," said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc Medicine. The company will present six poster presentations spanning its three key therapeutic programs.
Bitopertin in Erythropoietic Protoporphyria
The company will present results from the HELIOS study, a Phase 2, open-label, long-term extension study of bitopertin in erythropoietic protoporphyria (EPP). According to Quisel, the data will further support "bitopertin's potential profile as the first disease-modifying treatment for EPP." The presentation, titled "Results from the HELIOS Study," will be delivered by Melanie Chin on Saturday, June 14, at 6:30 pm CEST.
DISC-0974 for Myelofibrosis Anemia
Three presentations will focus on DISC-0974, an anti-hemojuvelin antibody being studied in patients with myelofibrosis and anemia. The company plans to share "additional durability data and new analyses from the Phase 1b study of DISC-0974 in patients with MF anemia," according to Quisel.
The presentations include a Phase 1b/2 study overview presented by Sima Bhatt, laboratory correlates of major anemia response in non-transfusion-dependent patients presented by Ayalew Tefferi, and preclinical data on combination therapy with ESA and/or luspatercept presented by Min Wu. All three presentations are scheduled for Friday and Saturday, June 13-14.
DISC-3405 Development Program
Two presentations will cover DISC-3405, a recombinant humanized antibody targeting TMPRSS6. The company will present new data from studies in healthy volunteers that "supports its progression into a Phase 2 study in polycythemia vera in the first half of this year and its broader potential in diseases of iron overload," Quisel noted.
Guowen Liu will present an iron pulse study assessing oral iron absorption following DISC-3405 treatment, while Marcus Carden will present data on single- and multiple-ascending doses showing increased hepcidin and reduced iron and hematocrit in healthy volunteers.
Corporate Update and Future Milestones
Management will host a corporate update conference call on Monday, June 16, at 8:00 am ET / 2:00 pm CEST to review the presented data. The call registration is available on the Events and Presentations page of Disc's website.
Company Focus and Pipeline Strategy
Disc Medicine is building a portfolio of innovative, potentially first-in-class therapeutic candidates that target fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. The company's approach aims to address a wide spectrum of hematologic diseases through these targeted pathways.
The abstracts are available through the EHA conference website, though according to company practice, the published abstracts contain previously presented data, with new data and analyses reserved for presentation at the conference.
